IL-33/ST2 axis in inflammation and immunopathology

Area of Science:

• Immunology
• Molecular Biology
• Cell Biology

Background:

• Interleukin-33 (IL-33) is an IL-1 family cytokine that signals through a receptor complex involving ST2L and IL-1R accessory protein.
• IL-33 can function as an alarmin upon cell damage or as an intracrine regulator of gene transcription.
• ST2L is expressed on various immune cells, including lymphocytes, myeloid cells, and granulocytes.

Purpose of the Study:

• To investigate the multifaceted role of the IL-33/ST2 axis in experimental models of autoimmune diseases and cancer.
• To explore the therapeutic potential of targeting the IL-33/ST2 pathway in immune-mediated conditions.

Main Methods:

• Utilized experimental models of type 1 diabetes, experimental autoimmune encephalomyelitis (EAE), Concanavalin A (Con A)-induced hepatitis, and breast cancer.
• Employed ST2-deficient mice and IL-33 administration to assess the impact on disease development and immune responses.
• Analyzed immune cell populations, cytokine production (IFN-γ, IL-17, TNF-α), and cell cytotoxicity.

Main Results:

• ST2 deletion exacerbated T cell-mediated autoimmune disorders (EAE, type 1 diabetes) and Con A hepatitis, associated with Th1/Th17 responses.
• IL-33 administration protected against Con A-induced liver damage by preventing hepatocyte apoptosis and promoting Th2 responses.
• Deletion of the IL-33/ST2 axis enhanced NK cell cytotoxicity and IFN-γ production, leading to attenuated tumor growth, while IL-33 treatment suppressed NK cell activity.

Conclusions:

• The IL-33/ST2 axis exhibits context-dependent roles, potentially promoting autoimmune inflammation but offering protection in certain conditions like hepatitis.
• IL-33 demonstrates attenuated anti-inflammatory effects in T cell-mediated responses.
• Both IL-33 and ST2 represent promising therapeutic targets for immune-mediated diseases.